Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma-Reference-Cited by-同舟云学术

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

Published:2021-03-01 Issue:3 Volume:7 Page:421
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sohal Davendra P. S.¹,Duong Mai²,Ahmad Syed A.¹,Gandhi Namita S.³,Beg M. Shaalan⁴,Wang-Gillam Andrea⁵,Wade James L.⁶,Chiorean E. Gabriela⁷,Guthrie Katherine A.²,Lowy Andrew M.⁸,Philip Philip A.⁹,Hochster Howard S.¹⁰

Affiliation:

1. Division of Hematology and Oncology, University of Cincinnati, Cincinnati, Ohio

2. SWOG Statistical and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, Washington

3. Cleveland Clinic, Cleveland, Ohio

4. University of Texas Southwestern Medical Center, Dallas

5. Division of Oncology, Washington University in St Louis, St Louis, Missouri

6. Cancer Care Specialists of Illinois, Decatur

7. University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle

8. Department of Surgery, University of California, San Diego, La Jolla

9. Medical Oncology, Karmanos Cancer Institute, Detroit, Michigan

10. Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2775174/jamaoncology_sohal_2021_oi_200106_1632334388.72421.pdf

Reference22 articles.

1. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.;Sohal;J Natl Cancer Inst,2014

2. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.;Neoptolemos;Lancet,2017

3. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.;Conroy;N Engl J Med,2018

4. Neoadjuvant therapy is essential for resectable pancreatic cancer.;Xu;Curr Med Chem,2019

5. Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?;Antonios;Future Oncol,2017

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma;Surgical Clinics of North America;2024-10

2. Preoperative Chemotherapy Does Not Impact Failure to Rescue in Patients Undergoing Pancreatectomy;Journal of Surgical Research;2024-10

3. BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug;Biomaterials;2024-09

4. Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinoma;Journal of Surgical Oncology;2024-08-19

5. Testing new anticancer drugs before curative locoregional therapies: MDICT 2024 recommendations;ESMO Open;2024-08